SubsidieMeestersA transcatheter functional valve replacement for tricuspid valve insufficiency
Innoventric's EIC project aims to clinically validate the Trillium, a minimally invasive transcatheter valve replacement for treating tricuspid regurgitation, improving patient outcomes.
Projectdetails
Introduction
Tricuspid regurgitation (TR) is a cardiac disorder in which the tricuspid valve leaks during systole, causing blood backflow and resulting in decreased cardiac output.
Prevalence and Progression
TR is the most common valvular heart disease, affecting 65%-85% of the global population in its mild form. However, mild TR can progress to severe TR, leading to heart failure or death if left untreated.
Current Treatment Options
Today, the only option for treatment is valve repair or replacement through open-heart surgery, which is associated with high mortality rates, risks, and costs.
Patient Statistics
Over 3 million patients suffer from TR in Europe, and for the majority, their condition is too severe for surgery; therefore, there is no effective treatment.
Innovative Solution
Innoventric has developed the Trillium - a transcatheter tricuspid valve replacement solution. The whole procedure is minimally invasive and can be completed in 30 minutes.
Project Goals
Within the EIC project, Innoventric will finalize the clinical validation of its device, ensuring safe and timely intervention for TR patients.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 5.525.003 |
Tijdlijn
| Startdatum | 1-6-2022 |
| Einddatum | 31-5-2026 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- INNOVENTRIC LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Transcatheter Ventricular Repair Device for treatment of Heart Failure PatientsCardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing. | EIC Accelerator | € 2.500.000 | 2022 | Details |
A prosthetic heart valve for adults and children, made from the patient’s own tissue, a replacement heart valve that lasts a lifetimeGrOwnValve aims to revolutionize heart valve technology by creating lifelong autologous valves from patients' own tissue using 3D printing, reducing rejection and the need for multiple surgeries. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Minimally invasive suturing for vascular bore closure and heart defect repairNovelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patientsreBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients. | EIC Accelerator | € 2.499.999 | 2023 | Details |
First in class lateral meniscus prothesis to relieve pain and restore mobility for KOA patientsATRO Medical's Trammpolin is a minimally invasive knee prosthesis designed to relieve pain and restore mobility in severe KOA patients, aiming for market entry in 2026 with a focus on health economics for reimbursement. | EIC Accelerator | € 2.499.402 | 2023 | Details |
Transcatheter Ventricular Repair Device for treatment of Heart Failure Patients
Cardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing.
A prosthetic heart valve for adults and children, made from the patient’s own tissue, a replacement heart valve that lasts a lifetime
GrOwnValve aims to revolutionize heart valve technology by creating lifelong autologous valves from patients' own tissue using 3D printing, reducing rejection and the need for multiple surgeries.
Minimally invasive suturing for vascular bore closure and heart defect repair
Novelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures.
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.
First in class lateral meniscus prothesis to relieve pain and restore mobility for KOA patients
ATRO Medical's Trammpolin is a minimally invasive knee prosthesis designed to relieve pain and restore mobility in severe KOA patients, aiming for market entry in 2026 with a focus on health economics for reimbursement.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
biomimetic engineered chordae tendineae for valve repair and regenerationThis project aims to develop and validate BioChord, a bioengineered regenerative chordae tendineae for mitral valve repair, enhancing durability and promoting tissue restoration. | ERC Proof of... | € 150.000 | 2023 | Details |
Prognostic assessment of valvular aortic disease treatment coupling Immunological and biomechanical profilesProtego aims to develop a predictive methodology combining immunological and biomechanical profiles to optimize treatment timing and outcomes for patients with aortic valve diseases, reducing complications. | ERC Starting... | € 1.498.295 | 2024 | Details |
Flow Controlled Prosthetic Heart ValvesStreamlineValve aims to develop a flow-controlled prosthetic heart valve that enhances durability and safety while reducing the need for anticoagulation therapy through optimized blood flow. | ERC Proof of... | € 150.000 | 2024 | Details |
Transcription Factor Gene Therapy for BradyarrhythmiasPacingCure's TRACTION project aims to optimize and validate BradyTx-01, a gene therapy for cardiac pacing dysfunctions, ensuring safety, efficacy, and a pathway to commercialization. | EIC Transition | € 2.499.968 | 2023 | Details |
Clonal hematopoesis of indeterminate potential and degenerative aortic valve stenosisThis project aims to investigate the impact of DNMT3A mutations on aortic valve stenosis progression and cardiac fibrosis, seeking biomarkers and therapeutic targets for high-risk patients. | ERC Advanced... | € 2.225.906 | 2022 | Details |
biomimetic engineered chordae tendineae for valve repair and regeneration
This project aims to develop and validate BioChord, a bioengineered regenerative chordae tendineae for mitral valve repair, enhancing durability and promoting tissue restoration.
Prognostic assessment of valvular aortic disease treatment coupling Immunological and biomechanical profiles
Protego aims to develop a predictive methodology combining immunological and biomechanical profiles to optimize treatment timing and outcomes for patients with aortic valve diseases, reducing complications.
Flow Controlled Prosthetic Heart Valves
StreamlineValve aims to develop a flow-controlled prosthetic heart valve that enhances durability and safety while reducing the need for anticoagulation therapy through optimized blood flow.
Transcription Factor Gene Therapy for Bradyarrhythmias
PacingCure's TRACTION project aims to optimize and validate BradyTx-01, a gene therapy for cardiac pacing dysfunctions, ensuring safety, efficacy, and a pathway to commercialization.
Clonal hematopoesis of indeterminate potential and degenerative aortic valve stenosis
This project aims to investigate the impact of DNMT3A mutations on aortic valve stenosis progression and cardiac fibrosis, seeking biomarkers and therapeutic targets for high-risk patients.